Malignant astrocytic glioma: genetics, biology, and paths to treatment
FB Furnari, T Fenton, RM Bachoo… - Genes & …, 2007 - genesdev.cshlp.org
Malignant astrocytic gliomas such as glioblastoma are the most common and lethal
intracranial tumors. These cancers exhibit a relentless malignant progression characterized …
intracranial tumors. These cancers exhibit a relentless malignant progression characterized …
'Pseudopalisading'necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis
Y Rong, DL Durden, EG Van Meir… - … of Neuropathology & …, 2006 - academic.oup.com
Glioblastoma (GBM) is a highly malignant, rapidly progressive astrocytoma that is
distinguished pathologically from lower grade tumors by necrosis and microvascular …
distinguished pathologically from lower grade tumors by necrosis and microvascular …
m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program
The dynamic and reversible N 6-methyladenosine (m 6 A) RNA modification installed and
erased by N 6-methyltransferases and demethylases regulates gene expression and cell …
erased by N 6-methyltransferases and demethylases regulates gene expression and cell …
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
AS Guerreiro Stucklin, S Ryall, K Fukuoka… - Nature …, 2019 - nature.com
Infant gliomas have paradoxical clinical behavior compared to those in children and adults:
low-grade tumors have a higher mortality rate, while high-grade tumors have a better …
low-grade tumors have a higher mortality rate, while high-grade tumors have a better …
Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma
SK McBrayer, JR Mayers, GJ DiNatale, DD Shi… - Cell, 2018 - cell.com
IDH1 mutations are common in low-grade gliomas and secondary glioblastomas and cause
overproduction of (R)-2HG.(R)-2HG modulates the activity of many enzymes, including some …
overproduction of (R)-2HG.(R)-2HG modulates the activity of many enzymes, including some …
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified in
gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel …
gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel …
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Both genome-wide genetic and epigenetic alterations are fundamentally important for the
development of cancers, but the interdependence of these aberrations is poorly understood …
development of cancers, but the interdependence of these aberrations is poorly understood …
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and
isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that …
isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that …
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Mutations affecting isocitrate dehydrogenase (IDH) enzymes are prevalent in glioma,
leukemia, and other cancers. Although mutant IDH inhibitors are effective against leukemia …
leukemia, and other cancers. Although mutant IDH inhibitors are effective against leukemia …
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
LGT Morris, AM Kaufman, Y Gong, D Ramaswami… - Nature …, 2013 - nature.com
Aberrant Wnt signaling can drive cancer development. In many cancer types, the genetic
basis of Wnt pathway activation remains incompletely understood. Here, we report recurrent …
basis of Wnt pathway activation remains incompletely understood. Here, we report recurrent …